Qrons Inc. (QRON)
USD 0.15
(-3.23%)
USD 0.15
(-3.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.48 Million USD | 16.09% |
| 2022 | 1.28 Million USD | 12.7% |
| 2021 | 1.13 Million USD | 51.31% |
| 2020 | 751.94 Thousand USD | 19.09% |
| 2019 | 631.41 Thousand USD | 612.88% |
| 2018 | 88.57 Thousand USD | 66.16% |
| 2017 | 53.3 Thousand USD | 1277.42% |
| 2016 | 3870.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.23 Million USD | -15.92% |
| 2024 Q1 | 1.47 Million USD | -0.94% |
| 2023 FY | 1.48 Million USD | 16.09% |
| 2023 Q4 | 1.48 Million USD | 4.47% |
| 2023 Q2 | 1.31 Million USD | -2.78% |
| 2023 Q3 | 1.42 Million USD | 8.4% |
| 2023 Q1 | 1.35 Million USD | 5.45% |
| 2022 Q3 | 1.22 Million USD | -5.8% |
| 2022 Q4 | 1.28 Million USD | 4.43% |
| 2022 FY | 1.28 Million USD | 12.7% |
| 2022 Q1 | 1.37 Million USD | 20.82% |
| 2022 Q2 | 1.3 Million USD | -5.17% |
| 2021 Q3 | 1.02 Million USD | 5.19% |
| 2021 Q2 | 977.23 Thousand USD | 1.59% |
| 2021 Q1 | 961.96 Thousand USD | 27.93% |
| 2021 FY | 1.13 Million USD | 51.31% |
| 2021 Q4 | 1.13 Million USD | 10.69% |
| 2020 Q3 | 792.6 Thousand USD | 16.48% |
| 2020 Q4 | 751.94 Thousand USD | -5.13% |
| 2020 FY | 751.94 Thousand USD | 19.09% |
| 2020 Q1 | 727.11 Thousand USD | 15.16% |
| 2020 Q2 | 680.49 Thousand USD | -6.41% |
| 2019 Q1 | 101.61 Thousand USD | 14.72% |
| 2019 FY | 631.41 Thousand USD | 612.88% |
| 2019 Q4 | 631.41 Thousand USD | 37.33% |
| 2019 Q3 | 459.77 Thousand USD | 68.46% |
| 2019 Q2 | 272.92 Thousand USD | 168.6% |
| 2018 Q4 | 88.57 Thousand USD | 21.85% |
| 2018 FY | 88.57 Thousand USD | 66.16% |
| 2018 Q1 | 69.99 Thousand USD | 31.3% |
| 2018 Q2 | 69.3 Thousand USD | -0.98% |
| 2018 Q3 | 72.68 Thousand USD | 4.88% |
| 2017 Q2 | 10.13 Thousand USD | 7.31% |
| 2017 FY | 53.3 Thousand USD | 1277.42% |
| 2017 Q3 | 79.48 Thousand USD | 684.47% |
| 2017 Q4 | 53.3 Thousand USD | -32.93% |
| 2017 Q1 | 9442.00 USD | 143.98% |
| 2016 Q4 | 3870.00 USD | 0.0% |
| 2016 FY | 3870.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5326.723% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 84.273% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.946% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -84.066% |
| Rebus Holdings, Inc. | 5.24 Million USD | 71.6% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.477% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -21.407% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.013% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3230.752% |
| Skye Bioscience, Inc. | 14.07 Million USD | 89.421% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.207% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 84.463% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -253.137% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.025% |
| Intellipharmaceutics International Inc. | 12 Million USD | 87.603% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 61.346% |
| Mesoblast Limited | 188.44 Million USD | 99.21% |
| Marizyme, Inc. | 26.67 Million USD | 94.419% |
| Genus plc | 485 Million USD | 99.693% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 74.52% |
| Pharming Group N.V. | 244.07 Million USD | 99.39% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 25.939% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 40.838% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 60.823% |
| ContraFect Corporation | 32.53 Million USD | 95.424% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 24.862% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 61.106% |
| IMV Inc. | 37.93 Million USD | 96.075% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 87.36% |
| MultiCell Technologies, Inc. | 1617.67 USD | -91928.226% |
| ONE Bio Corp. | 27.49 Million USD | 94.586% |
| Accustem Sciences Inc. | 1.07 Million USD | -37.941% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.077% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 29.614% |
| Q BioMed Inc. | 8.13 Million USD | 81.695% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.205% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 71.071% |
| Biomind Labs Inc. | 1.49 Million USD | 0.661% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.746% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 83.536% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.911% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -3.825% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -947.689% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -640.226% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 74.091% |
| GB Sciences, Inc. | 5.41 Million USD | 72.521% |
| Alpha Cognition Inc. | 7.16 Million USD | 79.222% |
| HST Global, Inc. | 593.59 Thousand USD | -150.797% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -18.228% |
| Halberd Corporation | 728.71 Thousand USD | -104.292% |
| Enzolytics Inc. | 365.26 Million USD | 99.592% |
| Agentix Corp. | 2.51 Million USD | 40.702% |
| Resverlogix Corp. | 67.39 Million USD | 97.791% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -77.496% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.665% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 13.144% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.984% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 87.493% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 59.382% |
| AVAX Technologies, Inc. | 3.99 Million USD | 62.724% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5299.953% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.888% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -523.796% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 60.134% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -118.66% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 45.099% |
| Kadimastem Ltd | 3.5 Million USD | 57.524% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2124.317% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.038% |
| BioStem Technologies, Inc. | 15.9 Million USD | 90.64% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -220.361% |
| LadRx Corporation | 2.2 Million USD | 32.347% |
| Cell Source, Inc. | 15.8 Million USD | 90.582% |
| Regen BioPharma, Inc. | 5.45 Million USD | 72.722% |
| Regen BioPharma, Inc. | 5.45 Million USD | 72.722% |
| NovAccess Global Inc. | 7.86 Million USD | 81.061% |
| Affymax, Inc. | 8.87 Million USD | 83.218% |
| Itoco Inc. | 1.65 Million USD | 9.947% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 27.435% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 75.389% |
| Mobile Lads Corp. | 1.31 Million USD | -13.34% |
| CytoDyn Inc. | 127.89 Million USD | 98.836% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3461.6% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 4.958% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 86.522% |
| SYBLEU INC | 681.41 Thousand USD | -118.474% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 75.602% |
| International Stem Cell Corporation | 5.27 Million USD | 71.789% |
| Bioxytran, Inc. | 3.24 Million USD | 54.186% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -137.886% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 67.757% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.369% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 93.314% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 26.497% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 72.824% |
| Neutra Corp. | 973.52 Thousand USD | -52.919% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.869% |
| PureTech Health plc | 125.58 Million USD | 98.815% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 60.376% |
| IXICO plc | 1.9 Million USD | 21.659% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 92.748% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.559% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Cellectis S.A. | 249.36 Million USD | 99.403% |